ecancermedicalscience

Research

Imatinib in gastrointestinal stromal tumour: Northern Cancer Network Experience

14 Dec 2009
F Azribi, ARA Razak, P Dildey, J Adam, J Wilsdon, M Verrill

Imatinib treatment in metastatic or inoperable gastrointestinal stromal tumours (GIST) has shifted the paradigm of treatment of this disease. Successful clinical trials of imatinib led to rapid regulatory approval and, in England and Wales, National Institute for Health and Clinical Excellence (NICE) guidance on use of this technology. NICE recommend detailed audit of their guidelines in clinical practice. This audit reflects that guidance and was designed to document the use of imatinib in routine clinical practice.

Methods: We conducted a retrospective audit of patients with GIST treated with imatinib from 1 February 2002 to 31 March 2007. Information gathered included patient demographics, disease characteristics and details of treatment administered, treatment response, toxicities and follow-up data. The primary objective was to record disease control rate (DCR), defined as a lack of progression on computed tomography at three months. Secondary end points of this audit were progression-free and overall survival. These were compared with published clinical trial results.

Results: Thirty-six consecutive patients with a diagnosis of GIST treated with imatinib were identified. Median age of patients was 70.1 years. At the time of analysis, patients have been followed up for a median of 41.6 months. In total, patients were treated for a median of 15.8 months. Treatment was generally well tolerated with a small percentage of patients experiencing grade 3/4 toxicities. Disease control was observed in 30 patients (DCR, 83.3%, 95% CI 67.2–93.6, intention to treat analysis). The median progression free survival (PFS) in this cohort was 23.7 months (95% CI 12.9–34.4); while the median overall survival was 39.7 months (95% CI 22.8–56.5).

Conclusion: Our data demonstrated that the treatment of unselected GIST patients within the NICE guidance compares favourably to previously published data of randomized registration studies of imatinib. Of note, the median age of this cohort is some ten years older than that reported in the trials. Imatinib was well tolerated with acceptable treatment-related adverse events.

Related Articles

Nikhil Bathija, Rohit Mahajan, Anil Kumar Goel, Siva Ranjani, Mounika Sirimalla, Gourav Kaushal, Sapna Marcus, Shilpa Jain, Madhur Verma, Deep Shikha, Korukonda Vinod Kumar, Jyoti Sharma
Loreto Fernández-González, Rodrigo Lagos, Piero Bettoli, Loreto Moreira, Jaime Sapag, David Kissane
Pablo Companys, Tomas Soule, Mariano Aymar, María Natalia Gandur Quiroga, Rosalía Hinojosa Altamirano, Marcelo Fogtman, Augusto Ferreyra Camacho, Rodrigo Sánchez, Gonzalo Taetti, Gabriela Gatica, Natalia Soto, María Elisa Arroyo, Nicolas Mainardi, Carolina Passarella, Andrea Marchioni, Ignacio Jerez, María Pía Domínguez, Emiliano Menna, Harold Somerville, Ernesto Korbenfeld, Florencia Sarru, Karina Peters, Iván Macharashvili, Federico Losco, Laura Pelagatti Santoni, Mauricio Fernández Lazaro, José Zarba, Mabel Gill, Juan Pablo Sade, Federico Cayol
Gbenro E. Olukiran, Adewumi O. Alabi, Anthonia C. Sowunmi, Babatunde Fadipe, Gbenga O. Popoola, Sunday A. Okinbaloye, Hnin L. Nwe Thein, Ololade Kehinde
Neha Singh, Sujata Agrawal, Zachariah Chowdhury, Shashikant Patne, Ipsita Dhal, Paramita Paul, Sadaf Haiyat, Akhil Kapoor, Anuj Gupta, Bal Krishna Mishra, Mayank Tripathi, Bipinesh Sansar
Edwin Saji, Jason Jacob, Udaya Kumar Damodaran, Sabah Kulsum, Sharanya Tripathi, Akshat Saxena, Panah Parab, Utkarsh Dayal, Priyal Dilip Mehta, Aju Mathew